Short Interest in Profusa, Inc. (NASDAQ:PFSA) Drops By 77.4%

Profusa, Inc. (NASDAQ:PFSA) was the recipient of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 53,192 shares, a decrease of 77.4% from the June 30th total of 234,995 shares. Approximately 28.8% of the shares of the company are sold short. Based on an average daily volume of 282,122 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analyst Weigh In

PFSA has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a report on Wednesday, June 24th. Wall Street Zen raised shares of Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Profusa presently has an average rating of “Sell”.

Profusa Stock Down 2.8%

Shares of NASDAQ:PFSA opened at $1.71 on Friday. Profusa has a 52 week low of $1.60 and a 52 week high of $4,162.50. The business has a fifty day simple moving average of $5.12 and a 200-day simple moving average of $44.19. The company has a market cap of $324,900.00, a P/E ratio of -0.00 and a beta of 0.46.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.